• In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders
• It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio
• For 2022, the company plans to build on the progress achieved in 2021
• With new additions to its board, its conditional IRB approval, and the clinical research it has lined up for the new year, Mydecine is confident that it will meet its anticipated capital markets initiatives for 2022

Founded in 2020, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) has pushed the envelope, particularly in innovating both first- and second-generation novel therapeutics for the treatment of unmet needs in mental health and addiction disorders. Over the past couple of years, it has pursued indications including, but not limited to Post-Traumatic Stress Disorder (“PTSD”), addiction and anxiety, and has made significant progress while at it. In 2021 the company made significant strides toward creating and commercializing new treatments for mental health and addiction disorders, and received conditional IRB approval to advance its Phase 2b smoking cessation study, which the company is confident will yield FDA Investigational New Drug (“IND”) approval in Q2 2022 (https://ibn.fm/sv7UB). More importantly, the year marked a significant shift for the company, focusing on reducing its expenses and increasing efficiencies in a bid to continue progressing its clinical trials and expanding its intellectual property (“IP”) portfolio. As of December 31, 2021, Mydecine had $1.5 million in cash and cash equivalents. Additionally, the company secured additional funding for its clinical trials and its IP portfolio expansion projects. Going forward, Mydecine plans to focus on clinical research, particularly Phase 2b of its smoking cessation clinical study, along with drug development, mainly highlighted by its Artificial Intelligence (“AI”) drug discovery program. “Over the last year, our new chemical entity (“NCE”) program has produced multiple patents covering several second-generation novel molecules that we believe will offer significant improvements over classic psilocybin and MDMA,” noted Rob Roscow, the Chief Scientific Officer at Mydecine. “We’re using a modular development approach to our patent strategy, which gives us the flexibility to license, partner or develop our lead drug candidates from our multiple families of NCEs, all wholly owned by Mydecine,” he added. In 2021, the company filed several provisional and full patent applications for novel molecules with the potential to outperform first-generation compounds safely. These applications covered novel MDMA analogs, improved psilocybin, other tryptamines, and potential heart-safe micro-dosing drugs, among others. Its management is confident that these patents will aid in taking the company to the next level in terms of performance and creating value for its shareholders. Mydecine also announced new independent board member appointments, including Gordon Neal, Josephine Wu, Dr. Saeid Babaei, and Dr. Victoria Hale. They bring a wealth of experience in drug development, clinical trials, and technology, and will be integral to the company meeting its anticipated capital markets initiatives for 2022. Mydecine is optimistic about the new year. With great things lined up, from clinical trials to new drug developments, the company is confident that it will help push the industry forward and create incredible value for its shareholders. “I’d like to personally thank our shareholders, board members, and highly dedicated team for enabling Mydecine to reach these significant milestones, and we look forward to another successful year,” noted Josh Bartch, Mydecine’s Chief Executive Officer (“CEO”). For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• The company exhibited at the premier event, held March 31–April 1, 2022
• ACT has worked to strengthen its presence in the cannabis space
• This strategic positioning comes as the global cannabis packaging market is projected to reach $297.51 billion by 2026

Advanced Container Technologies (OTC: ACTX) recently wrapped up a successful appearance at the CannaCon Conference, showcasing its new product line and strengthening brand awareness. The company exhibited at the premier event, held March 31–April 1, 2022, alongside Grassfire Distro, ACT’s exclusive packaging reseller (https://ibn.fm/WqmI3). Prior to the two-day event, Advanced Container Technologies CEO Doug Heldoorn noted that ACT had experienced “tremendous success” at last year’s CannaCon Conference. “We have an extensive line of new and exciting products that can help cannabis companies maximize profits throughout the ecosystem — from the cultivator to the retailer,” he stated. Since its participation in CannaCon last year, Advanced Container Technologies has worked to strengthen its presence in the cannabis space. Recognizing that safe, quality packaging in the sector is essential, ACT offers an impressive line of products, including an array of options for virtually every type of cannabis and hemp product, branding solutions, controlled environment cultivation systems, lighting, nutrients and a variety of other essential items. Most recently, the company launched its Store ‘n Seal bags, a new line of premium-quality packaging (https://ibn.fm/O4KVM). The new commercial-grade bags are leak proof, odor proof and watertight, and are designed to store vegetables, lettuce, leafy greens and even cannabis safely. The bags, which feature thick 5ml plastic with a resealable zipper across the top, are available in two varieties: a silver bag with a see-through window and a black-out bag. Each bag holds up to two pounds of product. This strategic positioning comes as the global cannabis packaging market is projected to reach $297.51 billion by 2026, with a CAGR of 22.59% (https://ibn.fm/yf57Z). ACT’s quality options aren’t going unnoticed; the company recently reported year-over-year revenues that show a 209% increase over the prior period, and company management expects that trend to continue. “We believe that we are in a stronger position than most of our competitors who are hampered by enormous operating expenses and dwindling growth rates,” says Heldoorn. “With our focus on remaining nimble and keeping costs and operating expenses as low as possible, we are in an excellent position to continue to grow rapidly outperform our competition in many key indicators.” “As the cannabis market continues to become more competitive, it becomes even more important for companies to find new ways to increase profitability,” Heldoorn added. “Our unique product line can help companies grow brands, deepen customer loyalty, and increase profits.” Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented, proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com. NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://ibn.fm/ACTX

 

• NEI reports strong bipartisan support for nuclear energy throughout the 117th Congress
• Hallmark pieces of legislation have demonstrated that carbon-free, always-on nuclear power is an indispensable driver of our clean energy future
• Institute notes that more can be done “to ensure gigawatts of electricity remain on the grid and new reactors are deployed”

Clean energy has become a top priority worldwide, and the U.S. is no exception. House representatives and senators in the nation’s capital have spent plenty of time talking about and voting on energy, including nuclear energy, and many companies, including Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), are paying attention to what’s happening in Washington, DC. “There has been strong bipartisan support for nuclear energy throughout the 117th Congress,” reported the Nuclear Energy Institute (“NEI”), the policy organization of the nuclear technologies industry, in a recent blog (https://ibn.fm/evlYU). “Decarbonization efforts and the clean-energy transition have received heightened attention on the Hill, and hallmark pieces of legislation have demonstrated that carbon-free, always-on nuclear power is an indispensable driver of our clean energy future. “In November, Congress passed the bipartisan $1.2 trillion infrastructure package, which featured major investments in nuclear energy,” the article continued. “The bill contained continued funding for the Advanced Reactor Demonstration Program (‘ARDP’), a demonstration program for Regional Clean Hydrogen Hubs, and support for operating nuclear plants at risk of closure.” The blog mentioned the Build Back Better Act, which is currently on the back burner but contains “broadly supported climate provisions [that] include a production tax credit (‘PTC’) for electricity generated by nuclear power plants in operation today, as well as tax credits for all clean electricity technologies, including advanced nuclear and power uprates that begin construction after 2026,” the piece continued. “The bill also includes funding for the development of a domestic high-assay low-enriched uranium (‘HALEU’) supply, a fuel which is essential to the demonstration of advanced reactors, as well as resources to support efforts such as the coal to nuclear transition.” The NEI piece also noted that the importance of nuclear was being acknowledged in other pieces of critical legislation, including the National Defense Authorization Act (“NDAA”), which was passed in December and “recognized the role advanced nuclear will play in both our national security and climate goals. The Department of Defense will work to deploy microreactors, helping to advance these technologies into commercialization so that they can provide clean energy to remote areas.” In addition, the blog called out several smaller, nuclear-specific bills introduced during this Congress. “These sustained, bipartisan efforts to advance nuclear energy signal a push to meet our climate goals, while also providing jobs and stimulating local economies with new nuclear,” the blog stated. Those bills included the American Nuclear Infrastructure Act (“ANIA”); the Advanced Nuclear Deployment Act; the Nuclear Licensing Efficiency Act; the Modernize Nuclear Reactor Environmental Reviews Act; and the Accelerating Nuclear Innovation through Fee Reform Act; the Fission for the Future Act; the Strengthening American Nuclear Competitiveness Act; and an historic budget request for nuclear from the administration in 2021. “While a bipartisan coalition has boldly committed to supporting new nuclear and protecting operating plants, there is more to be done to ensure gigawatts of electricity remain on the grid and new reactors are deployed,” the blog concluded. “Incentivization programs that value carbon-free energy and fund the next generation of climate technologies, such as advanced nuclear, are essential to meeting our climate goals.” A member of the NEI, Energy Fuels is keenly interested in what happens on a federal level. The company operates three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch ISR Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of more than 8 million pounds of U₃O₈ per year. The mill is also currently in commercial production of the most advanced rare earth element material being produced in the U.S. today. The mill also produces vanadium when market conditions warrant. The Nichols Ranch ISR Project is currently on standby and has a licensed capacity of 2 million pounds of U₃O₈ per year. The Alta Mesa ISR Project is also currently on standby. In addition to these production facilities, Energy Fuels has one of the largest NI 43-101-compliant uranium resource portfolios in the country, along with several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• The security robot market was valued at $8.87 billion in 2020 and is expected to grow to $19.77 billion by 2026
• Knightscope’s autonomous security robots bridge the gap between unmet security needs and the security demands of a rising population
• The committed equity facility provides Knightscope with the right to sell and issue up to $100 million of its Class A Common Stock

Since the pandemic, an increased need for autonomous technology in the private security and asset protection industries has become apparent, resulting in a growing market for these solutions. The most recent census reported 325 million people living in the United States, but there are only approximately 700,000 local, state, and federal police officers to protect the population – an industry shortage that can be compensated through the implementation of security robots, like the K5 by Knightscope (NASDAQ: KSCP). As technological developments in the industry evolve, security robots are benefited from improved automation and sensor technology capabilities. Development and improvement in neural network technology have given robots the ability to learn over time – improving overall functionality. As a result, the security robot market is constantly expanding, from $8.87 billion in 2020 to an anticipated value of $19.77 billion by 2026, registering a CAGR of close to 14% during the forecast period of 2021-2026 (https://ibn.fm/g3p7F). Knightscope is a Silicon Valley-based company specializing in advanced security technologies and constructing autonomous security robots (“ASRs”) that deter, detect, and report. Knightscope recently met the security needs of a Silicon Valley commercial real estate (“CRE”) twin-tower office complex, deploying its K5 ASR to answer the property manager’s need for a security strategy for the building’s stakeholders (https://ibn.fm/iYWwV). Knightscope’s K5 ASR is a fully autonomous outdoor security robot with over one million hours of logged, commercially operated service with the ability to run 24/7. With indoor and outdoor terrain capabilities, the K5 has a maximum speed of 3 mph, weighs 398 pounds, and measures 36” (L) x 33.5” (W) x 62.5” (H). Integrated with the Knightscope Security Operations Center (“KSOC”), a browser-based user interface, human eyes can use the real-time data for autonomous detection, including:

• Force Multiplying Physical Deterrence
• Eye-Level 360-Degree HD Video Streaming and Recording
• People Detection During Certain Restricted Hours
• Thermal Anomaly Detection
• Automatic Signal Detection
• License Plate Recognition

The K5 is also weatherproof, allowing outdoors operation, even in adverse conditions. The ASR was also created with ramp accessibility in mind. Knightscope is also making it possible for clients to meet their line of ASRs – through the Robot Roadshow. Clients can either visit virtually or schedule a pod visit on the company’s website. Knightscope recently marked its 9th anniversary (April 4) and announced on the occasion that it had entered into a $100 million common stock purchase agreement with B. Riley Principal Capital. The committed equity facility provides Knightscope with the right (without obligation) to sell and issue up to $100 million of its Class A Common Stock over a period of 24 months to B. Riley at its own discretion – more details can be found in the Form 8-K to be filed by Knightscope with the SEC. “I believe about 95% of startups fail, and the odds of starting a company, growing it, and taking it public are likely in the winning-the-lottery type of odds… but we stuck together and did it with the help of all of our partners! Congratulations and many thanks to the entire Knightscope team, our clients, investors, and suppliers,” Knightscope’s chairman and CEO William Santana Li said, commenting on the 9-year milestone for the company (https://ibn.fm/2TJXi). For more information about Knightscope, visit the company’s website at www.Knightscope.com, and if you are considering subscription service you can request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

• Through three acquisitions, EverGen Infrastructure Corp. has rapidly emerged as a leading player in the RNG market with its specialization in waste-to-energy
• EverGen owns the first producing RNG facility in Western Canada and calls municipalities and FortisBC as customers
• EverGen recently signed an LOI to expand into Alberta through the acquisition of 67% of a RNG project that has already been contracted to supply RNG to FortisBC

To many, a waist-deep heap of rotting food and agricultural waste is just garbage, but to Chase Edgelow, Chief Executive Officer of EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF), it is a valuable resource and opportunity to generate profits while doing something good for the planet. Less than two years from inception, EverGen, which brands itself as Canada’s Renewable Natural Gas (“RNG”) Infrastructure Platform, has established itself as a pioneer in the RNG market, snapping up several facilities in the process, including penning an LOI for a controlling stake in in a biogas facility in Alberta in March. RNG, a term used to describe biogas upgraded as a substitute for fossil natural gas, is critical to a clean energy future. Produced from any number of feedstocks, including municipal solid waste, livestock, food, and material from digesters at wastewater treatment plants, RNG can be used in many applications, including heating and cooling, electricity generation, and fuel for many different types of vehicles, amongst other things. This, in turn, saves not only on natural resources, but eliminates all the pollution from the extraction and downstream processes. Moreover, using the organic waste as feedstock can have a meaningful impact on the reduction of ozone-damaging methane emissions created through other disposal methods. Infinity Business Insights sees a thriving global RNG market undergoing 42.1% compound annual growth that will take it from $5.3 billion in 2021 to $62.1 billion by 2028. It is with good reason that Canadian companies including Enbridge Inc., ATCO Energy Solutions, and FortisBC have initiatives ongoing in the space. FortisBC’s has a stated target to have at least 15% of its gas supply carbon neutral by 2030. Headquartered in Vancouver, British Columbia and incorporated in May 2020, EverGen has quickly made a name for itself in its mission to own and operate a portfolio of RNG, waste-to-energy, and related infrastructure projects throughout North America.  With an initial focus in Western Canada, the company operates three facilities through its wholly owned B.C.-based subsidiaries: Net Zero Waste Abbotsford Inc. (“NZWA”), Sea to Sky Soils and Composting Inc. (“SSS”) and Fraser Valley Biogas Ltd. (“FVB”). All three companies were acquired by EverGen in a four-month span from December 2020 to April 2021. FVB has the distinction of being the first producing RNG project in Western Canada from its facility in Abbotsford. It also was the first project to produce RNG into FortisBC’s network. The facility combines anaerobic digestion and biogas upgrading to produce RNG, primarily by converting agricultural waste from local dairy farms. EverGen also generates revenue (in fact, historically most of its revenue) through processing inbound organics, yard waste and biosolids into high-quality organic compost under long-term contracts with municipalities. However, the trend towards RNG is accelerating as the push for a circular energy economy gains momentum. In its favor, EverGen has some powerful relationships and customers in municipalities and FortisBC, an electricity and natural gas distribution utility serving approximately 1.2 million British Columbians. In addition to the FVB/FortisBC agreement, the relationship was deepened last April when FortisBC and NZWA agreed to a 20-year offtake agreement. Per the agreement, which was approved by the British Columbia Utilities Commission in October, FortisBC will purchase up to 173,000 gigajoules of RNG annually from NZWA for injection into its natural gas system. The project is expected to convert municipal and commercial organic waste into enough energy to meet the needs of approximately 1,900 residential homes. From this existing platform, EverGen plans to further develop RNG facilities to provide offtake to FortisBC and other creditworthy buyers under long term contracts. With the regulatory path now clear and development and construction ongoing, NZWA expects to be supplying FortisBC with its RNG by early 2023. EverGen, which completed its initial public offering that raised CDN$20.0 million in August, generated CDN$1.94 million in revenue during the third quarter, bringing the total for the first nine months of 2021 to CDN$6.87 million. In March, EverGen took its first step to expand the next province over, executing a letter of intent with Grow the Energy Circle Ltd (“GrowTEC,” the general partner of CKPPQ Farms LP), to acquire a 67% interest in a biogas facility in Alberta. The LOI also stipulates that the two companies will collaborate on developing and expanding the renewable gas output at such facility, a “cornerstone” project allowing EverGen to continue participating in the consolidation and growth of the RNG industry. EverGen has agreed to pay CDN$6.6 million for the controlling interest though CDN$3.3 million in cash and the balance through issuance of 600,000 shares of common stock at a deemed value of CDN$5.50 per share, a 19.8% premium to the price of the stock the day before the LOI was executed. GrowTEC, located on the Perry Family farm near Lethbridge, Alberta, is a multi- faceted bioenergy venture of sustainable agriculture, integrating responsible best practices and renewable energy. The acquisition dovetails perfectly with EverGen’s growth agenda, as GrowTEC is developing a project that include a farm-scale anaerobic digester that converts biodegradable waste into biogas, subsequently upgrading it to RNG. FortisBC is again in the mix, with the utility committed to buying RNG produced at the farm under an offtake agreement. The project is currently in Phase 1, which is expected to be producing 80,000 gigajoules of RNG per annum starting in Q3 2022. Upon the EverGen investment, the two parties will work to increase production to 140,000 gigajoules of RNG annually. “We are thrilled to be partnering with GrowTEC and working with the Perry Family Farm on EverGen’s first project in the Alberta market,” said Edgelow in a press release on the LOI. “As we expand our RNG infrastructure platform, we are focused on investing in truly sustainable operations that contribute to carbon-negative energy production and positively impact climate change initiatives,” he added. EverGen shareholders will be on the lookout for the completion of the transaction, which is expected to happen before summer arrives. For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Agriculture generates approximately 19-29% of total global greenhouse gas emissions and also has the highest demand for ammonia, at 80% globally
• This demand for ammonia is contributing to an increase in greenhouse gas emissions, through its production and additional processes
• FuelPositive seeks to remedy this situation with its on-site green ammonia production technology
• Through its decentralized agricultural positioning model, the company aims to reduce ammonia’s overall carbon footprint while also empowering farmers by giving them fertilizer and energy independence and control over supply and costs

Experts have noted, with great concern, that the current food production and distribution systems are already at a breaking point. They have cited the need to feed a growing global population as one of the key factors creating tremendous pressure on a structure that, they note, has been pushed to its environmental limits (https://ibn.fm/H3EIb). FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) recognizes this issue and, through its green ammonia technology, the company is trying to remedy the situation and offer solutions that are not only sustainable but also accessible, even to the ordinary farmer. Over the years, the agricultural sector has dealt with various challenges, from an aging and shrinking workforce to a significant loss of arable land and, more importantly, the potentially disastrous effects of climate change. According to a report from The World Bank, agriculture remains a significant part of the climate problem, generating approximately 19-29% of total global greenhouse gas (“GHS”) emissions (https://ibn.fm/ypSHv). In addition, agriculture is the sector with the highest demand for ammonia, accounting for over 80% globally. Ammonia is integral for adding nitrogen into the soil, an element that is essential for plant growth and plant health. Usually, the nitrogen is depleted by growing crops, prompting farmers to replenish it using ammonia. The issue, however, arises from ammonia production. Typical manufacturing of this product is energy-intensive and centralized, resulting in some of the world’s most concentrated greenhouse gas emissions. Additionally, there is an issue with supply chain interruptions and wild price fluctuations that affects farmers and adds to other processes that only increase the carbon footprint. FuelPositive seeks to remedy the situation with its decentralized agriculture positioning for its green ammonia. For starters, the company’s product aims to give farmers fertilizer and energy independence. With every farm housing a FuelPositive production unit scaled up or down based on its needs, the farmers will produce sufficient ammonia to fertilize their crops and even power their internal combustion engines in their farm equipment, and generators on the farm (https://ibn.fm/qntgM). This opens even more opportunities for farmers, including converting propane and natural gas crop-drying systems to burn green ammonia as a way to realize an exceptional environmental benefit. This decentralized approach eliminates the traditional supply chain, which is wildly unpredictable, both in supply and cost. Farmers will have control over the amount of ammonia and fuel they produce and when it will be available to them. They will be able to plan on a steady price, giving them a chance to increase their margins and improve their livelihoods from their farming activities. In addition, from an environmental standpoint, the unique ammonia production process eliminates reliance on fossil fuels, and the decentralization of the production facilities negates ammonia’s overall carbon footprint, allowing for a healthier planet. FuelPositive is able to help the agricultural sector reduce its overall greenhouse gas emissions while providing more opportunities for farmers to make a decent living from their operations. In addition, through its push for green ammonia and its push for more farmers to access it, the company is creating even more value for its shareholders. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine”
• Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically
• SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications

“The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as a result, psychiatry may never be the same. This isn’t news for companies such as Silo Pharma (OTCQB: SILO). A developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, Silo has long been familiar with the potential of psychedelics. “It’s been a long, strange trip in the four decades since Rick Doblin, a pioneering psychedelics researcher, dropped his first hit of acid in college and decided to dedicate his life to the healing powers of mind-altering compounds,” reported the Times, noting that psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. “Even as antidrug campaigns led to the criminalization of Ecstasy, LSD and magic mushrooms, and drove most researchers from the field, Dr. Doblin continued his quixotic crusade with financial help from his parents. “Dr. Doblin’s quest to win mainstream acceptance of psychedelics took a significant leap forward on Monday when the journal ‘Nature Medicine’ published the results of his lab’s study on MDMA, the club drug popularly known as Ecstasy and Molly,” the article continued. “The study, the first phase 3 clinical trial conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder.” The article observed that only a few weeks ago, the “New England Journal of Medicine” also published a study highlighting the benefits of treating depression with psilocybin, the psychoactive ingredient in magic mushrooms. These studies “have excited scientists, psychotherapists and entrepreneurs in the rapidly expanding field of psychedelic medicine. They say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically — for MDMA as soon as 2023, followed by psilocybin a year or two later. After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction. The need for new therapeutics has gained greater urgency amid a national epidemic of opioid abuse and suicides.” This urgency aligns with Silo Pharma’s mission identifying assets to license while funding transformative research for the well-being of patients and the healthcare industry. The company focuses specifically on patients suffering from largely underserved indications like post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. The company has filed four U.S. provisional patent applications and a pipeline including a research collaboration with Columbia University and UCSF; an investigator-led sponsored study with Maastricht University; an option agreement with the University of Maryland, Baltimore for patented homing peptides targeting rheumatoid arthritis; licensing for a patented novel peptide-guided drug-delivery approach for the treatment of multiple sclerosis; and upfront funding for a licensing deal for its psilocybin cancer therapeutic applications. Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the healthcare industry. For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• TravelAdvisor survey shows demand for travel remains high with majority of respondents likely to travel this year
• Survey also reports that the average spend per trip for 2022 is estimated to be beyond that of 2019
• SHRG’s new company will offer tremendous savings, exclusive benefits to its members

Calling 2022 “the year of the travel rebound,” TripAdvisor announced results of a recent survey indicating that traveler intent for this year demonstrates high demand for booking experiences and a willingness to spend more on travel (https://ibn.fm/YL42V). This is great news for Sharing Services Global (OTCQB: SHRG), which last year launched a new travel company, a direct-selling division focused on providing exclusive benefits and first-class discount travel opportunities (https://ibn.fm/Rh3O9). The TripAdvisor report, which was conducted in partnership with Ipsos MORI, indicates how consumers are planning to travel in 2022 and beyond, and how their attitudes toward and plans for travel have changed compared to prepandemic. “While outside factors like COVID-19 variants, international travel rules and staffing shortages still can represent existential threats to traveler behaviors, year-end sentiment and search data show ongoing demand for travel remains high,” a summary of the report stated. “Who benefits from the tourism demand? As travelers spend more, cultural experience providers (tours and attractions), tourism businesses catering to domestic audiences and companies adhering to safety standards will win the hearts and minds of travelers.” The survey, which was conducted in November 2021, included more than 10,000 participants aged 18 to 75 in the United States, United Kingdom, Australia, Singapore and Japan. Respondents were asked about their sentiments regarding their future travel inclinations, when they plan to travel, and what they’re looking for in a trip when they do. Across the five markets, the majority of respondents indicated that they were either very likely or fairly likely to travel for leisure, to travel to visit friends or family, or to travel for business purposes this year. Specifically, the report noted that “respondents in Singapore were the most likely to say they will travel in 2022 at 89%, followed by respondents in the UK at 85%. Australia and the United States fell in the middle of the five markets surveyed, with 79% and 78%, respectively, saying that they are likely to travel for those reasons in 2022. Japanese respondents were the least likely to say they will travel in 2022, with 58% saying that they are likely to do so — still a healthy proportion of people despite being the lowest of the five markets surveyed.” In addition, TripAdvisor reported that the average amount spent per trip for 2022 is estimated to be beyond that of 2019, as travelers look to level up their travel experience. According to Tripadvisor, American travelers are expected to spend 29% more on their average trip in 2022 than they did in 2019, while in Australia, average booking rates are expected to be up by 16% in 2022 against 2019. Singaporean travelers’ booking values are also expected to increase this year. SHRG’s news of its travel company, one of its Hapi Brands subsidiaries, will be ideally positioned to benefit from these upward trends. According to Sharing Services, to differentiate itself from its competitors, the new company will offer its members unfettered access to tremendous savings and exclusive benefits on a level not seen in the industry before. Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com, www.TheHappyCo.com, and www.HapiTravel.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• CNS Pharmaceuticals is a clinical stage biotechnology company focused on the development of novel treatments for brain tumors
• The company’s lead product candidate, Berubicin, is a novel anthracycline that is designed to cross the blood-brain barrier
• The blood-brain barrier ordinarily hinders the vascular delivery of therapeutic substances to brain tumors
• By crossing this protective barrier, Berubicin holds promise for the thousands of adult Americans diagnosed with malignant central nervous system cancers annually

This year, about 25,050 adults (14,170 men and 10,880 women) will be diagnosed with malignant central nervous system (“CNS”) tumors – cancerous tumors that start in the spinal cord or brain. The figure represents an increase from an estimated 24,530 cases documented last year. Of these statistics, the American Society of Clinical Oncology (“ASCO”) notes that brain tumors account for 85-90% of all primary CNS tumors (https://ibn.fm/c9ThB). But despite this prevalence, the treatment of brain tumors has long been complicated by the brain’s internal workings. A healthy human brain has a mechanism known as the blood-brain barrier that protects the active functions of the CNS and blocks toxins and microorganisms from passing through the highly picky semipermeable border. While this barrier promotes stability of the sensitive internal environment of the brain, it complicates the treatment of brain tumors. Most notably, it hinders the vascular delivery of various therapeutic substances, including anthracyclines, to the cancerous growths within the brain’s internal environment (https://ibn.fm/YZGPK). “[Anthracycline] is a classic drug that’s been around for 60 years. It’s the first line therapeutic for all sorts of difficult-to-treat cancers. But no one has been able to get a drug like this across the blood-brain barrier until our Founder modified the classic anthracycline molecule to be more effective in crossing the blood-brain barrier,” CNS Pharmaceuticals (NASDAQ: CNSP) President & CEO John Climaco told Proactive last fall (https://ibn.fm/em55b). Following the modifications, now woven into the company’s lead product candidate, Berubicin – a novel anthracycline designed to concentrate in tumor tissue within the brain – CNS Pharmaceuticals is targeting the treatment of glioblastoma multiforme (“GBM”). GBM, also known as a grade IV astrocytoma, is the most malignant, aggressive, and common form of astrocytoma – a type of brain cancer – and is one of the most treatment-resistant cancers that form in the brain (https://ibn.fm/fed4R). Historically, a GBM diagnosis often led to a prognosis of months or less to live. But this narrative is changing, with research and clinicians’ work helping prolong patients’ lives. Founded in 2017, CNS Pharmaceuticals is leading the charge toward advancing research on the treatment for GBM as well as other primary and metastatic brain and CNS cancers. Last year, the company commenced a potentially pivotal clinical trial of Berubicin for the treatment of GBM, dosing its first patients in September (https://ibn.fm/cE5xu). The company expects to report an interim analysis of the trial when 30-50% of the planned subjects reach six months in-study, potentially in the first half of 2023. The adaptive, multicenter, open-label, randomized, and controlled study will involve about 243 adult patients with recurrent GBM after failure of standard first-line therapy. The subjects will be randomized in a 2:1 ratio to receive Berubicin or lomustine, a compound used in chemotherapy, to evaluate Overall Survival, the study’s primary endpoint. The study is expected to potentially build on the Phase 1 trial and pharmacokinetic study of Berubicin, whose results revealed that 44% of the patients showed clinical response of stable disease or better, with one patient demonstrating a lack of detectable cancer cells and two patients with partial tumor reduction of up to 80%. In a recent update, CNS Pharmaceuticals also celebrated the production of a new mesylate salt of its WP1244 drug technology, now known as WP1874, whose improved solubility may enhance its ability to be formulated for use in an IV infusion. WP1874 is believed to retain the potency and toxicity attributes of WP1244, which, in turn, was shown to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Moving forward, CNS Pharmaceuticals expects to primarily focus its development efforts of the WP1244 portfolio on the newly minted WP1874. The company is also investigating the use of WP1244/WP1874 in treating other primary CNS cancers as well as brain metastases such as pancreatic, ovarian, and lymphoma (https://ibn.fm/CLVDb). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Recent study forecasts global mental health market to reach almost $538B by 2030
• One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and more
• Cybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders

A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated to reach $537.97 billion by 2030, growing at a compound annual growth rate of 3.5% from 2021 to 2030 (https://ibn.fm/J7hfJ). With three active drug programs targeting mental-health disorders, Cybin (NEO: CYBN) (NYSE American: CYBN) is establishing itself as a leader in revolutionizing mental health treatments. “Mental health problems are characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms,” the recent Allied Market Research report states. “Increase in prevalence of mental disorders, rise in geriatric population, and growth in awareness programs regarding mental health drive the market growth. Moreover, growing awareness about mental disorders through education and advocacy for more respect of human rights and less stigma drive the growth of the global mental health market.” Noting that one in five people in the United States suffers from mental illness, the report cites alcohol use disorders, bipolar disorder, depression, anxiety, post-traumatic stress disorder, substance abuse disorders, and eating disorders as some of the major categories in the mental-health space. The study reported that the depression segment dominates the market and is expected to continue this trend throughout the forecast period. “Factors such as genes as well as stress and brain chemistry lead to depression,” the report states. “According to the WHO, more than 264 million people of all ages suffered from depression in 2020. Depression is a leading cause of disability worldwide, and is a major contributor to the overall global burden of disease.” In its commitment to transform the mental health treatment landscape, Cybin is combining novel psychedelic molecules with controllable drug-delivery systems through its proprietary deuterated process, thus creating patent-protected, commercially scalable drug candidates. The company currently is moving three of these drug candidates forward: CYB003, CYB004 and CYB005 (https://ibn.fm/bqIt6). Cybin’s active drug programs target major depressive disorder (CYB003), alcohol use disorder (CYB003), anxiety disorders (CYB004) and neuroinflammation (CYB005).  The company recently announced that it commenced a company-sponsored feasibility study with its partner Kernel to evaluate Kernel’s quantitative neuroimaging technology, Kernel Flow(R). The Flow headset, which is equipped with hi-tech sensors, will be used to collect and quantify longitudinal brain activity before, during and after a psychedelic experience. Cybin also has 50 novel compounds developed with multiple patent filings across three patent families. In terms of investor interest, Cybin has raised $120 million to date to support its clinical trials and M&A strategy. In addition, the company is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN